ClinicalTrials.gg
CompletedNCT03174795Updated May 15, 2018

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

A Phase 1 interventional study of RO7079901 and Meropenem in Urinary Tract Infections, sponsored by Hoffmann-La Roche. Completed at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-15.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2017, 8 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Urinary Tract Infections with a site in Hungary — 2 open to participants now, 2 under way, none of them phase 3. Urinary Tract Infections · Hungary.

Enrollment
15th of 15
20 · median 598
Started
2017
with 2 others
Phase 1
2 of 19
none open now
Registered
9th of 19
by date
Lead sponsor
1 of 19
Hoffmann-La Roche

Among the 19 studies in Urinary Tract Infections with a site in Hungary, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 1, and was the 9th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

2 of the 19 studies in Urinary Tract Infections with a site in Hungary are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Urinary Tract Infections with a site in Hungary, or all of them as a file.
02

Study summary

This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.

03

Conditions studied

  • Urinary Tract Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Requiring hospitalization for IV antibacterial therapy for the treatment of presumed/confirmed cUTI (including pyelonephritis)
  • Clinical signs and/or symptoms of pyelonephritis or a cUTI
  • Urine culture taken within the 48 hours (hr) period immediately preceding the first dose of study drug contains greater than (>)1x10\^5 colony forming units (CFU) per milliliter (CFU/mL) of a gram negative organism
  • Negative urine pregnancy test result confirmed by a blood test
  • Agreement to remain abstinent or use a method

Exclusion criteria

Exclusion Criteria:

  • Has a concomitant infection requiring antibacterial therapy, in addition to study drug
  • Confirmed fungal urinary tract infection
  • Moderate or severe renal impairment, or end-stage renal disease requiring renal replacement therapy or a recipient of a renal transplant
  • Documented presence of immunodeficiency, or a severely condition or use of systemic immunosuppressant therapy
  • Any rapidly progressing disease or immediately life-threatening illness, or other terminal illness or condition with high risk of mortality meaning that the participant is considered, in the opinion of the Investigator, unlikely to survive the study period
  • Urinary tract surgery or urogenital trauma in the one week immediately preceding study entry
  • Urinary tract infection (UTI) symptoms potentially attributable to another process (sexually transmitted infections or prostatitis)
  • Suspected or confirmed perinephric or intra renal abscess
  • Complete obstruction of any portion of the urinary tract, or a permanent urinary diversion
  • History of epilepsy, brain lesions or other significant neurological disorders
  • Use of probenecid within the 7 days before enrollment
  • Known history of clinically significant or severe allergic reaction to meropenem or any other antibiotic
  • Any other ongoing condition or disease, or clinically significant abnormalities in laboratory test results that the investigator considers would render the participant unsuitable for the study
  • Women who are pregnant, planning to become pregnant, or lactating
  • Participation in a clinical study of an drug or device within one month prior to enrollment
  • Prior enrollment in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    RO7079901 and Meropenem

    Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.

    Drug: RO7079901 · Drug: Meropenem

Interventions

  • Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.

  • Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUC0-tau) of RO7079901

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  2. Total Clearance (CL) of RO7079901

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  3. Renal Clearance (CLr) of RO7079901

    Time frame: Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)

  4. Maximum Observed Plasma Concentration (Cmax) of RO7079901

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  5. Cumulative Amount Excreted in Urine Over the Dosing Interval (Ae) of RO7079901

    Time frame: Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)

  6. Fraction Excreted into the Urine (Fe) of RO7079901

    Time frame: Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)

  7. Time of Maximum Observed Plasma Concentration (Tmax) of RO7079901

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  8. Steady State Volume of Distribution (Vss) of RO7079901

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

Secondary outcomes

  1. AUC0-tau of Meropenem

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  2. CL of Meropenem

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  3. CLr of Meropenem

    Time frame: Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)

  4. Cmax of Meropenem

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  5. Ae of Meropenem

    Time frame: Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)

  6. Fe of Meropenem

    Time frame: Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)

  7. Tmax of Meropenem

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

  8. Vss of Meropenem

    Time frame: Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7

07

Study locations

14 sites
  • eStudySite
    La Mesa, California 91942, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • Semmelweis University, First Dept of Medicine
    Budapest, 1083, Hungary
  • Szent Imre Egyetemi Oktatokorhaz
    Budapest, 1115, Hungary
  • Kenezy Gyula Korhaz-Rend. Eges. Szol.; Klinikai Farm. Infek. es Allerg. Intezet
    Debrecen, 4012, Hungary
  • Liepaja Regional hospital
    Liepaja, 3414, Latvia
  • P.Stradina Kliniska Uni Tes Slimnica; Latvian Center of Nephrology
    Riga, LV-1002, Latvia
  • Riga East clinical university hospital
    Riga, LV1006, Latvia
  • Klinika Urologii Ogólnej: Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu; Urology
    Bydgoszcz, 85-094, Poland
  • Szpital Kliniczny Dzieciątka Jezus; Oddział Urologii
    Warszawa, 02-005, Poland
  • Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek
    Łódź, 92-213, Poland
  • Clinical Center of Serbia; Clinic of Urology
    Belgrade, 11000, Serbia
  • Clinical Center Zemun
    Belgrade, 11080, Serbia
  • Clinical Hospital Center Bezanijska Kosa
    Belgrade, 11080, Serbia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Dec 2017, 4 months.

Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2017
First posted
Jun 5, 2017
StartActual
Jul 11, 2017
Primary completionActual
Dec 4, 2017
CompletionActual
Dec 16, 2017
Last update
May 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03174795
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
Jul 11, 2017
Primary completion
Dec 4, 2017
Completion
Dec 16, 2017
Last update
May 15, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nacubactam

Start the discussion